SINT SINTX TECHNOLOGIES INC.

SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY

SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. () (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer and developer of advanced ceramic materials and related technologies, announced that its wholly owned subsidiary Technology Assessment & Transfer, Inc. (TA&T) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Army Research Laboratory (DEVCOM ARL). This partnership is expected to leverage the strengths of both organizations in the areas of ceramic additive manufacturing (ceramic 3D printing) and ceramic matrix composites (CMCs).

According to its website, the U.S. Army DEVCOM Army Research Laboratory is the U.S. Army’s research laboratory strategically placed under the Army Futures Command. DEVCOM ARL is the Army’s sole foundational research laboratory focused on cutting-edge scientific discovery, technological innovation, and transitioning capabilities for the future Army (See: ().

SINTX’s Millersville, MD facility, Technology Assessment and Transfer, Inc., began work on ceramic 3D printing in the mid 1990’s, printing its first component in 1998. SINTX now provides prototype and Low-Rate Initial Production (LRIP) ceramic 3D printing services, sells ceramic-filled resins that customers use in their own printing processes, and works with multiple customers in the development of printing solutions for new materials.

In parallel to ceramic 3D printing, SINTX’s Maryland site has also been developing ultra-high temperature CMCs, and building extensive capabilities in the densification of fiber-based preforms using both chemical vapor infiltration and polymer infiltration and pyrolysis. SINTX is excited to participate in the dramatic increase in the market need for these materials in hypersonic vehicle applications as one example.

Ann Kutsch, General Manager of the Maryland site, commented: “We have a highly skilled team of engineers and technicians here in Maryland, all of whom are instrumental in pushing this cutting-edge work forward. I look forward to optimizing our offerings in these markets while also working with DEVCOM ARL to build both teams’ knowledge and capabilities in advanced technologies.”

###

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.

For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including, but not limited to, statements regarding SINTX’s ability to effectively develop a range of innovative applications of our ceramic additive manufacturing capabilities, SINTX’s ability to commercialize its technologies and broaden the applications that benefit from such technologies, and other statements that are not based on historical fact. Such forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from current expectations. Risks and uncertainties that may cause such differences include, among other things: SINTX’s products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls and qualification standards; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of SINTX’s products once commercialized; risks related to manufacturing products and market acceptance volatility in the price of SINTX’s common stock; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2023, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
30/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies to Participate in Noble Capital Markets’ Emerging G...

SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company’s participation comes at an important stage in its evolution, following a period o...

 PRESS RELEASE

SINTX Technologies to Participate in Sidoti & Company Investor Confere...

SINTX Technologies to Participate in Sidoti & Company Investor Conference SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: To schedule a one-on-one meeting with SINTX Technologies’ management team, please email KCSA Strategic ...

 PRESS RELEASE

SINTX Technologies ลงนามในข้อตกลงจัดหาวัสดุกับ EVONIK เพื่อผลิตสารประก...

SINTX Technologies ลงนามในข้อตกลงจัดหาวัสดุกับ EVONIK เพื่อผลิตสารประกอบซิลิคอนไนไตรด์–PEEK สำหรับรากฟันเทียมเฉพาะบุคคลที่พิมพ์ 3 มิติ โดยใช้เทคโนโลยี AI เข้าช่วย ความสำเร็จครั้งสำคัญช่วยให้สามารถผลิตอุปกรณ์ SiN/PEEK แบบกำหนดเองได้ทันที เมืองซอลต์เลกซิตี รัฐยูทาห์ วันที่ , Dec. 02, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc.  (NASDAQ: SINT) (“SINTX” หรือ “บริษัท”) ซึ่งเป็นบริษัทด้านเซรามิกส์และวัสดุชีวภาพขั้นสูง ได้ประกาศในวันนี้ว่า บริษัทได้ลงนามในข้อตกลงจัดหาวัสดุกับ Evonik Corporation (“EVONIK”) ซึ่งเป็นผู้นำระดับโลกด้านโพลิเมอร์ประสิทธิภาพสูง เพื่อผลิตสารประกอบซิลิคอนไนไตรด์–P...

 PRESS RELEASE

SINTX Technologies 与 EVONIK 签署供应协议,将生产用于人工智能辅助 3D 打印患者定制植入物的氮化硅-PEEK 复...

SINTX Technologies 与 EVONIK 签署供应协议,将生产用于人工智能辅助 3D 打印患者定制植入物的氮化硅-PEEK 复合材料 该里程碑使 SiN/PEEK 定制器械能够立即投产 犹他州盐湖城, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先进陶瓷和生物材料公司 SINTX Technologies, Inc. (NASDAQ: SINT) (简称“SINTX”或“公司”)今天宣布,已与高性能聚合物领域的全球领导企业 Evonik Corporation(简称“EVONIK”)签署供应协议,由 EVONIK 生产 SINTX 的专有氮化硅-PEEK 复合材料(SiN/PEEK,美国专利号 10806831)。该材料专为人工智能辅助的患者定制植入物增材制造而设计,并将使用 SINTX 位于美国的现有生产设施完成制造。 根据协议,EVONIK 将利用其商业规模生产能力,按照 SINTX 的规格生产 SiN/PEEK 复合材料,使 SINTX 能够立即开始制造人工智能设计 3D 打印患者定制植入物。 SINTX 公司已经收到医生提出的请求,希望该公司能为脊柱肿瘤切除术后的骨科和神经外科肿瘤患者提供用于人道主义用途的椎体置换 (VBR) 植入物。 此外,该公司计划使用 SiN/PEEK 复合材料支持患者匹配型植入物及采用传统减材制...

 PRESS RELEASE

SINTX Technologies 與 EVONIK 簽署供應協議,生產用於人工智能輔助 3D 打印患者專屬植入物的氮化矽–PEEK 複合...

SINTX Technologies 與 EVONIK 簽署供應協議,生產用於人工智能輔助 3D 打印患者專屬植入物的氮化矽–PEEK 複合材料 此里程碑讓 SiN/PEEK 定制儀器得以即時投產 猶他州鹽湖城, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先進陶瓷與生物材料公司 SINTX Technologies, Inc. (NASDAQ: SINT) (「SINTX」或「該公司」) 今日宣佈,已與高性能聚合物全球領導者 Evonik Corporation (「EVONIK」) 簽署供應協議,生產該公司專利的氮化矽–PEEK(即聚醚醚酮)複合材料 (SiN/PEEK) (美國專利編號:10,806,831),此材料專為人工智能 (AI) 輔助增材製造患者專屬植入物而設計,將運用 SINTX 美國生產基地現有設備來生產。 根據協議,EVONIK 將發揮達到商業規模的生產能力,按照 SINTX 規格生產 SiN/PEEK 複合材料,使該公司能夠立即開始製造由 AI 設計、3D 打印的患者專屬植入物。SINTX 已收到醫生請求,為脊椎腫瘤切除後的骨科及神經外科腫瘤患者,提供人道使用的椎體替換(VBR)植入式儀器。此外,該公司打算運用 SiN/PEEK 複合材料,支援患者匹配及傳統減材製造植入式儀器的監管批准。 SINTX 主席、董事長暨行...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch